1246202-96-9Relevant academic research and scientific papers
Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474
Giddens, Anna C.,Gamage, Swarna A.,Kendall, Jackie D.,Lee, Woo-Jeong,Baguley, Bruce C.,Buchanan, Christina M.,Jamieson, Stephen M.F.,Dickson, James M.J.,Shepherd, Peter R.,Denny, William A.,Rewcastle, Gordon W.
, p. 1529 - 1545 (2019)
Replacing one of the morpholine groups of the phosphatidylinositol 3-kinase (PI3K) inhibitor ZSTK474 with a variety of sulfonamide-linked solubilizing substituents produced a new class of active and potent PI3Kα inhibitors, with several derivatives demonstrating high PI3Kα enzyme potency and good cellular potency in two human derived cell lines. The overall results suggest a preference for linear and somewhat flexible solubilizing functions. From this series, compound 16, also known as SN32976, was selected for advanced preclinical evaluation.
PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY
-
Page/Page column 74, (2010/10/19)
Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides, e.g., compounds of Formulae IA, IB, and IC, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.
